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Introduction
Much of the public media discussion of
genetics of common diseases has centered
on opportunities for targeted preventive
actions. At the same time, in the specialist
literature, there has been extensive discus-
sion of ‘‘interaction,’’ both between genes
and between genes and environment.
These two topics concern the use and
interpretation of statistical models for risk
of diseases with several, perhaps many,
etiological risk factors, and were both the
subject of lively debate some 30 to 40 years
ago when such models first came into
widespread use in epidemiology. Here
these debates are revisited and illustrated
with results from an analysis of the
genetics of type 1 diabetes (T1D). Details
of this analysis are provided in section 1 of
Text S1.
Prediction
Attempts to predict risk of disease from
multiple risk factors began in the early
1960s, mainly in the context of coronary
heart disease [1]. The logistic regression
model soon became the method of choice,
an early example being the five-year
coronary disease risk score calculated from
the Framingham cohort study data [2].
Predictive power of such models is often
summarized by a receiver operating char-
acteristic (ROC) curve; subjects are ranked
in descending order of their predicted risk
and the cumulative proportion of subjects
who eventually succumb (cases) is plotted
against the corresponding cumulative pro-
portion of the population. Figure 1 illus-
trates such a plot using the Framingham
data as an example; 29.6% of cases fell in
the highest decile of predicted risk in the
population, 46.6% fell in the top quintile,
and so on. In terms of the use of the
prediction score in a screening test, the
ROC curve plots the sensitivity against
(one minus) the specificity [3] for all
possible thresholds for the score. A third
measure of the accuracy of a screening test
is the positive predictive value (PPV), the
proportion of screen-detected patients who
will go on to develop disease. For a rare
event such as serious disease incidence, the
ratio of true positives to false positives,
PPV/(12PPV), is given by multiplying the
population risk by the ratio of the ordinate
to the abcissa of the ROC curve. Although
there have been many attempts to repre-
sent predictive efficacy in terms of a single
number [4], such indices are often mis-
leading, and it will generally be necessary
to consider the whole curve when assessing
the usefulness of prediction for clinical or
public heath purposes.
Initial hopes that multivariate risk scores
could form the basis of a prevention
program based on targeted intervention
in high-risk subjects quickly foundered
owing to inadequate prediction. Rose [5]
eloquently described the difficulty as the
‘‘prevention paradox,’’ in which ‘‘a large
number of people at low risk may give rise
to more cases of disease than the small
number who are at high risk.’’ In terms of
the ROC curve, the problem is that the
ratio of ordinate to abcissa is usually only
high enough to achieve an acceptable PPV
at the very high end of the spectrum of
risk, and this contributes a relatively small
proportion of total cases. With the excep-
tion of screening for presence of early-
stage disease, these arguments led to a
swing away from the strategy of targeted
intervention in favor of preventive strate-
gies aimed at entire populations.
Interest in the possibility of individual-
ized approaches to prevention and treat-
ment has recently been reawakened in the
context of advances in genetics. For
example, Sir George Radda, then chief
executive of the Medical Research Coun-
cil, stated: ‘‘In 20 years’ time, we may see
individualized approaches to disease pre-
vention and treatment’’ [6]. Ironically,
such public pronouncements came at a
time when complex disease genetics
seemed to be making little headway [7].
Recent successes of genome-wide associa-
tion studies have established a more
optimistic climate of opinion, but it
remains unclear whether such advances
have the potential to deliver sufficiently
accurate predictions to make targeted
intervention a realistic possibility. In
common with many such statements,
Radda’s remarks bracket prevention and
treatment, but there are important differ-
ences, notably in the frequency of out-
comes and in the need for high PPVs.
While, in the treatment of disease, inaction
is rarely an option and any prediction,
however imperfect, may lead to benefit to
patients, a preventive strategy based upon
targeting high-risk subgroups will usually
require more accurate prediction in order
to be both ethical and effective from a
public health standpoint.
It now seems that most genetic associ-
ations for common diseases currently
being discovered are weak and, taken
alone, would provide limited prediction
[8–10]. However, a more open question is
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all relevant genetic loci were eventually
identified. This depends on the heritability
of the condition and the model for risk. In
the special case of many loci acting
multiplicatively as in the logistic regression
model, the ROC curve for prediction
from a set of loci can be deduced from
the sibling recurrence risk ls [11] (see also
section 2 of Text S1). Figure 2 shows a
series of such curves. The most extreme
curve corresponds to ls=15, typical of
values quoted for autoimmune diseases
such as T1D, multiple sclerosis, and
Crohn disease. This assumes that all
of the reported ls is attributable to
genetics rather than shared environment
and that all relevant loci have been
identified. Yet for diseases with cumulative
incidence below 1%, even this would
fail to deliver high PPV together with
high sensitivity. For diseases such as
type 2 diabetes and ischemic heart
disease, for which reported values of ls
are three or less, much of which may be
attributable to shared environment, the
ROC curves suggest that individual pre-
diction will be extremely poor, even if all
loci could be identified and taking account
of the rather greater frequency of such
conditions in the population. The more
extravagant claims for the utility of
genetics in targeted prevention would
therefore seem implausible, although it
has been suggested that genetic informa-
tion may have a more limited role in more
effective delivery of screening programs
[11].
T1D Analysis
Understanding of the genetic determi-
nants of T1D commenced with the
discovery, in 1973, of a strong HLA
association [12]. This was followed, in
1984, by discovery of the INS gene
association [13]. Subsequent progress was
slow, resulting in the discovery, by 2007, of
only three further associated loci in
candidate genes. However, the advent of
genome-wide association studies has re-
sulted in an explosion of new discoveries,
with more than 40 disease susceptibility
loci now identified [14]. The impact of
these discoveries on prediction are dis-
played in Figures 3, 4, and 5. Although the
new discoveries will have undoubted value
for our understanding of the disease, their
impact on prediction is modest.
Current known loci explain a ls of just
under five, as compared with the value of
15 often quoted. However, it is likely that
the latter figure is exaggerated, and the ls
attributable to inheritance is likely to be
less than ten. The heritability explained
will be increased to some degree when the
known regions are more fully studied, but
the bulk of the remaining heritability is
likely to be attributable to many small (or
rare) effects, most of which are unlikely to
be mapped. Thus, even for this highly
heritable disease, the prediction achievable
could fall some way short of that required
for a targeted prevention strategy.
Interaction
This topic has received much recent
attention, but with scant reference to the
lively debate of the early 1980s, which was
initiated in response to widespread over-
interpretation of ‘‘interaction’’ in logistic
regression models. It has been widely
noted that statisticians and biologists
attach different meanings to the word
‘‘interaction’’ [15–19]. Whereas a biologist
would use the word (often loosely) to
describe an aspect of biological mecha-
nism, for a statistician, interaction between
two factors represents deviation from some
mathematical model for joint effects of
several factors on risk. It only has an
Figure 1. ROC curve for the prediction score of Truett, Cornfield, and Kannel [2] (five-
year incidence of coronary heart disease in the Framingham cohort study).
doi:10.1371/journal.pgen.1000540.g001
Figure 2. Theoretical ROC curves for various values of ls under the polygenic
multiplicative model.
doi:10.1371/journal.pgen.1000540.g002
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ematical model tested has an interpreta-
tion. This is rarely the case; most mathe-
matical models are convenient fictions and
would certainly be rejected given sufficient
sample size. Writing in 1991, Thompson
[20] noted that, although much of the
debate had by then subsided, few clear
conclusions had emerged. His review
concluded: ‘‘[C]hoice among theories of
pathogenesis is enhanced hardly at all by
the epidemiological assessment of inter-
action…What few causal systems can be
rejected on the basis of observed results
would provide decidedly limited etiologi-
cal insight.’’ In following years, this has
been the consensus view among epidemi-
ologists—a fact that renders the recent re-
emergence of interest in genetic epidemi-
ology somewhat surprising.
In genetics, the confusion between
statistical and biological notions of inter-
action goes back to Fisher’s 1918 paper
[21] in which he used the term ‘‘epistacy’’
to describe statistical interaction between
different loci—a use to which a referee, R.
C. Punnett, objected [22]. The confusion
of which Punnett warned was further
increased as Fisher’s term ‘‘epistacy’’
became widely replaced by Bateson’s term
[23], ‘‘epistasis,’’ which inspired it [24–
27]. The difference between Fisher’s and
Bateson’s use of these terms illustrates a
distinction that statisticians draw between
‘‘quantitative’’ interaction and ‘‘qualita-
tive’’ interaction. In a quantitative inter-
action, presence of one factor is associated
with a larger or smaller effect of a second
factor, but the direction of effect is
unchanged. The presence of interaction
then depends on the way ‘‘effects’’ are
measured; if there is no interaction when
effects are measured by relative risks (as in
the logistic regression model), there would
be interaction if effects were to be
measured by differences in risk (as in an
additive risks model). And vice-versa.
This ambiguity contrasts with qualitative
interaction, where one factor reverses the
direction of effect of the other or, as in
Bateson’s epistasis, when presence of
one factor simply negates the effect of
another.
While qualitative interaction has clear
implications for mechanism, conventional
statistical tests for interaction do not test
for this. A test for reversal of direction of
effect has been proposed [28], but is rarely
used, and it is anyway arguable whether
such effects will be widespread in the
epidemiology of common diseases. Mask-
ing of effect is perhaps more plausible, but
it could be argued that formal proof of this
is impossible since this would require proof
of the hypothesis of no effect in a
subgroup. However, Berrington de Gon-
za ´lez and Cox [29] argued that to take the
position that only effect reversal provides
evidence of biological interaction risks
overlooking important findings. In prac-
tice, the size of effects is crucial. In
experiments with congenic strains of mice,
observed effects are often so large that it
can be reasonable to infer their absence
when they are not observed. In the context
of T1D, such work has recently been
reviewed by Ridgway et al. [30], who
concluded: ‘‘Using congenic mice, gene–
gene interactions and gene masking effects
have been observed that make large
impacts on the T1D frequency whereas
these effects are mostly hidden in a
genetically segregating population such as
a backcross one or an F2 generation, or in
Figure 3. ROC curves prediction from loci in the MHC region. Prediction using six single
nucleotide polymorphisms (SNPs) is shown in red, while prediction using HLA-DRB1 is shown in
green. These curves (and those in Figures 4 and 5) were obtained by fitting logistic regression
models as described in Text S1 and calculating the proportions of cases and controls with
prediction scores exceeding each possible value. The dashed curve corresponds to the theoretical
curve for the polygenic multiplicative model with ls=3.13.
doi:10.1371/journal.pgen.1000540.g003
Figure 4. ROC curve prediction from the SNPs outside the MHC region listed in
Supplementary Table 1 in Text S1 (in blue). The dashed curve corresponds to a polygenic
multiplicative model with ls=1.48.
doi:10.1371/journal.pgen.1000540.g004
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humans.’’
A model, it has been claimed, that does
allow a biological interpretation of quan-
titative interaction is the additive model
for risk, which corresponds (to a close
approximation) with the model of inde-
pendent sufficient causes [31] (for an
alternative view of this model see [32]).
Often, however, the model of independent
causes will be implausible a priori, and its
rejection would provide a ‘‘decidedly
limited etiological insight.’’ It often pro-
vides a decidedly poor fit to empirical
data, and the model usually preferred is
the logistic regression model, in which the
odds in favor of developing disease
(proportional to the risk, for rare diseases)
is given by the product of multiplicative
effects or, equivalently, by additive effects
on the log odds scale. To avoid confusion,
the term ‘‘additive model’’ will henceforth
refer to the model in which effects are
additive in risk. Unlike the additive risks
model, the logistic model has no simple
biological interpretation and is useful only
in so far as it provides an empirical
description of real phenomena, and quan-
titative interaction in this model will rarely
have a biological interpretation.
Despite the problems of interpreting
tests for quantitative interaction, statisti-
cally significant results are often heralded
as ‘‘significant’’ in a wider sense. An
example is the much cited work concern-
ing interaction of life stress and a poly-
morphism of the 5-HTT gene on depres-
sion [33]; although only quantitative
interaction tests are quoted, the figures
shown are suggestive of qualitative inter-
action (even though these only show fitted
values from regression equations). It seems
unlikely that the model of independent
causes would have fitted these data, but
one might question whether the a priori
support for this model would render its
falsification anything other than a ‘‘deci-
dely limited etiological insight.’’ Additional
evidence for the widespread overinterpre-
tation of quantitative interaction can be
found in the literature describing calcula-
tion of sample sizes necessary for its
detection [34–36].
Another reason for recent interest in
gene–gene interaction concerns its impli-
cations for association studies. It is argued
that the genetic effects currently being
detected are small, but that interaction
between genes is likely to be ubiquitous.
From these tenets it is concluded that
larger effects (and better prediction) will be
seen if we study genes two or more at a
time. A similar argument has been influ-
ential in generating interest in gene–
environment interactions. The effects of
environmental and behavioral factors on
disease risk are typically stronger than the
effects of genetic loci, but measuring them
in free-living populations is difficult and
prone to the well-documented problems of
bias, confounding, and reverse causality. It
has been argued that research into such
influences has reached its limits, effect sizes
being small in comparison with methodo-
logical errors [37]. Again a powerful
intuition is that, since genes and environ-
ment must interact, larger effects will be
found in genetically at-risk subgroups of
the population. However, such arguments
confuse statistical and biological interac-
tion; the fact that gene–gene and gene–
environment interaction, in the mechanis-
tic sense, are probably widespread does
not mean that statistical interaction in the
logistic regression model will be equally
widespread.
The possible role of interaction in the
detection of new associations is stressed in
emerging writings of computer scientists.
These approaches use measures of ‘‘syn-
ergy’’ derived from information theory
[38,39]. Synergy/interaction is judged to
be present when higher dimensional
contingency tables carry more information
than their lower order margins. The
precise measure of information synergy
proposed by these authors can be criti-
cized, but is quite close to a measure of
deviation from multiplicative effects. It can
be argued that a more satisfactory treat-
ment [40] leads to a definition of infor-
mation theoretic synergy that is precisely
the same as interaction in the logistic
regression model (see section 3 of Text S1).
Thus, entropy measures of synergy differ
little from standard tests for statistical
interaction in the logistic model and suffer
the same problems of interpretation. But
advocates of this approach have not been
immune to the tendency to confuse
mathematical and biological notions of
interaction. For example, Moore et al.
wrote [38]: ‘‘It is the promise of systems
biology to deliver an etiological under-
standing of epistasis.’’ There is often a
strong implication that genes that act
synergistically in this information theoretic
sense act in the same causal pathway—an
assumption that cannot be justified rigor-
ously.
In complex disease genetics, models for
additive and multiplicative contributions
to risk have both been discussed in some
detail. In the context of affected relative
pair linkage studies, Risch [41] considered
the additive model for risks as a close
approximation to the idea of ‘‘genetic
heterogeneity.’’ In contrast, he proposed
the multiplicative model for risks as a
model for epistasis and demonstrated that,
under this model, recurrence risks fall
away much more rapidly with increasing
distance of relationship than under the
additive model—as is observed for most
common complex diseases. Confusingly,
in the literature on association studies,
epistasis is more commonly identified with
deviation from the multiplicative model.
Epistasis has also been defined in terms of
departure from the multiplicative model
Figure 5. ROC curve prediction from all the SNPs listed in Supplementary Table 1 in
Text S1 (in blue). The prediction curve using the six MHC SNPs alone is shown in red, and the
dashed curve corresponds to a polygenic multiplicative model with ls=4.75.
doi:10.1371/journal.pgen.1000540.g005
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motivated by the same mathematics that
underlies the case-only test for gene–gene
interaction [42]: i.e., that under this
model, loci that are statistically indepen-
dent in the population remain so in cases.
Estimation of the joint effects of multi-
ple genes, or of genes and environment,
remains an important aim, but interpreta-
tion of statistical tests for presence or
absence of interaction are problematic.
The T1D example discussed below dem-
onstrates this.
T1D Analysis
The interaction between HLA and
PTPN22 illustrates the problem of inter-
pretation. As in previous reports [14,43–
46], the effect of PTPN22, measured by
relative risks, is greatest in the low-risk
HLA group (shown as the first entry in
each section of Table 1). This variation in
relative risks defines interaction in the
context of the multiplicative model, and is
measured by the ‘‘interaction’’ parame-
ters—the ratios of relative risks shown as
the second entry in each section of the
table. However, when main effects are
included and the results converted to
absolute risks (the final two entries in each
section of the table), it can be seen that the
additional risk due to PTPN22 is largest in
the high-risk HLA group. Since the risk
differences are not constant, there would
also be said to be interaction in the context
of the additive model, but it is in the
reverse direction. Neither the additive nor
the multiplicative model describe the joint
action of these two loci. Whereas deviation
from the additive model can be interpret-
ed as rejection of the model of indepen-
dent sufficient causes, rejection of the
multiplicative model has no biological
interpretation of which the author is
aware.
In logistic regression analysis of the
T1D data, there are many interactions
that achieve nominal (p,0.05) levels of
significance. But, with the exception of
strong interactions within the major histo-
compatibility complex (MHC), these in-
teractions are small and have a modest
effect on prediction, and their omission
leads to scarcely perceptible loss of pre-
diction. For example, the area under the
ROC curve for prediction using non-HLA
loci and allowing for interactions (Figure 4)
is 0.738, and this falls only to 0.733 when
all interaction terms are omitted.
Further analysis shows that the model
for additive accumulation of genetic risks
for T1D can be rejected beyond doubt,
but the multiplicative model, while not
perfect, provides a remarkably good ap-
proximation.
Conclusion
Many authors have recently comment-
ed on the modest predictive power of the
common disease susceptability loci cur-
rently emerging. However, here it is
suggested that, for most diseases, this
would remain the case even if all relevant
loci (including rare variants) were ulti-
mately discovered. It must also be said that
similar difficulties are faced when making
predictions on the basis of environmental
risk factors, as was recognized by epide-
miologists more than 30 years ago.
Prediction at the individual level is an
ambitious aim, particularly in the context
of disease prevention.
Similarly, the recent interest in interac-
tion in genetics has also been character-
ized by exaggerated expectations for the
inferences that can be drawn from epide-
miological data. These, too, were widely
prevalent in epidemiology thirty or more
years ago, but have since given way to
more limited expectations; aside from
rejection of a model in which two factors
operate through wholly unrelated mecha-
nisms, little can be deduced about mech-
anism from the observation of statistical
interaction—particularly when effects are
not large.
Supporting Information
Text S1 Prediction and interaction in
complex disease genetics: experience in
type 1 diabetes.
Found at: doi:10.1371/journal.pgen.
1000540.s001 (0.15 MB PDF)
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